I4T-JE-JVCW - ClinicalTrials.gov - NCT02539225
I4T-JE-JVCW - ClinicalTrials.gov - NCT02539225
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, confirmed by histology or cytology; participants with esophageal cancer are not eligible
Participants of reproductive potential (men and woman) must agree to use contraception (hormonal or barrier methods) during the study period and at least 6 months after the last dose of study treatment
Participant must be willing to provide a blood sample for research purposes
Participants must NOT
Participant must not have human epidermal growth factor receptor 2 (HER2)-positive status
Participant must not have known brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression
Female participant must not be pregnant or breast feeding. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to first dose of study treatment
Participant must not have any prior malignancies
Trial Summary
Conditions the trial is for
Stomach Cancer, Gastroesophageal Junction Cancer (GEJ)
What the trial is testing?
Part A: S1/Oxaliplatin + Ramucirumab or S1/Oxaliplatin + Placebo, Part B: Ramucirumab + Paclitaxel
Could I receive a Placebo?
yes
Enrollment Goal
190
Trial Dates
October 2015 - December 2021
Trial Phase
2
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, confirmed by histology or cytology; participants with esophageal cancer are not eligible
Participants of reproductive potential (men and woman) must agree to use contraception (hormonal or barrier methods) during the study period and at least 6 months after the last dose of study treatment
Participant must be willing to provide a blood sample for research purposes
Participants must NOT
Participant must not have human epidermal growth factor receptor 2 (HER2)-positive status
Participant must not have known brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression
Female participant must not be pregnant or breast feeding. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to first dose of study treatment
Participant must not have any prior malignancies
Trial Summary
Conditions the trial is for
Stomach Cancer, Gastroesophageal Junction Cancer (GEJ)
What the trial is testing?
Part A: S1/Oxaliplatin + Ramucirumab or S1/Oxaliplatin + Placebo, Part B: Ramucirumab + Paclitaxel
Could I receive a Placebo?
yes
Enrollment Goal
190
Trial Dates
October 2015 - December 2021
Trial Phase
2
Trial Locations
Hide locations not currently recruiting